Program
VERVE-102
A development code.
Its studies are mostly in Atherosclerosis · Hyperlipoproteinemia Type II, led by Eli Lilly.
Furthest: phase 2, since Sep 18, 20262 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 22 open or running | phase 2since Sep 18, 2026 | Dec 1, 2023 | Aug 2028phase 2 · NCT07839936 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2023First study: phase 1 study in Hyperlipoproteinemia Type IIFirst studyNCT06164730 · 85 planned · United States, Australia, Canada and more
- Sep 18, 2026Phase 2 study in AtherosclerosisPhase 2 reachedNCT07839936 · 175 planned · United States
Ahead
- Aug 2028Primary completion: phase 2 study in AtherosclerosisNCT07839936
TargetBeta
“VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C.”study text, read by Claude · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07839936Atherosclerosis · United States | 2 | Recruiting | Aug 2028 | 175 |
| NCT06164730Hyperlipoproteinemia Type II · United States, Australia, Canada and more | 1 | Recruiting | Oct 2026 | 85 |
How it is read
Names in the registry
- “VERVE-102”, 2 entries
Codes read as this program: VERVE102.
Conditions, from the studies’ own filings
- Atherosclerosis, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.